Interleukin-33 inhibitors - Pipeline Insight, 2025
Description
DelveInsight’s, “Interleukin-33 inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Interleukin-33 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Interleukin-33 inhibitors: Overview
IL-33 belongs to the IL-1 family of cytokines. IL-33 is a novel cytokine that signals through the ST2 surface receptor. IL-33 receptor has a single chain, which is also related to the IL-1 receptor (interleukin-1 receptor-like 1, IL-1RL1). Signal transduction upon ligand binding involves the Toll-like receptor (TIR) domain of the receptor chain and resembles that of IL-1 and IL-18, and TLRs. IL-33 exhibits diverse immune regulatory functions during the various phases of different diseases. IL-33 likely functions as a disease sensitizer and plays pathological roles in inflamed tissues in allergic disorders that involve hyperreactive immune responses. In contrast, IL-33 also mediates tissue-protective functions during the recovery phase following tissue injury, which involves activation of tissue-reparative M2 macrophages, ILC2s, and Tregs. IL-33 could be used against inflammation caused by Th1 response, and antagonists perhaps might be developed as anti-allergic compounds. Targeting the IL-33-ST2 axis using monoclonal antibodies (or small-molecule inhibitors) could prove to be an effective strategy against COVID-19 virus. The combination of IL-33 blockade with other therapeutics could be an option for the efficacious treatment of inflammatory diseases.
Report Highlights
This segment of the Interleukin-33 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin-33 inhibitors Emerging Drugs
Further product details are provided in the report……..
Interleukin-33 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin-33 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Interleukin-33 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin-33 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-33 inhibitors drugs.
Interleukin-33 inhibitors Report Insights
Current Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Interleukin-33 inhibitors: Overview
IL-33 belongs to the IL-1 family of cytokines. IL-33 is a novel cytokine that signals through the ST2 surface receptor. IL-33 receptor has a single chain, which is also related to the IL-1 receptor (interleukin-1 receptor-like 1, IL-1RL1). Signal transduction upon ligand binding involves the Toll-like receptor (TIR) domain of the receptor chain and resembles that of IL-1 and IL-18, and TLRs. IL-33 exhibits diverse immune regulatory functions during the various phases of different diseases. IL-33 likely functions as a disease sensitizer and plays pathological roles in inflamed tissues in allergic disorders that involve hyperreactive immune responses. In contrast, IL-33 also mediates tissue-protective functions during the recovery phase following tissue injury, which involves activation of tissue-reparative M2 macrophages, ILC2s, and Tregs. IL-33 could be used against inflammation caused by Th1 response, and antagonists perhaps might be developed as anti-allergic compounds. Targeting the IL-33-ST2 axis using monoclonal antibodies (or small-molecule inhibitors) could prove to be an effective strategy against COVID-19 virus. The combination of IL-33 blockade with other therapeutics could be an option for the efficacious treatment of inflammatory diseases.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-33 inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin-33 inhibitors.
This segment of the Interleukin-33 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin-33 inhibitors Emerging Drugs
- MEDI3506: AstraZeneca
- Itepekimab: Regeneron Pharmaceuticals/Sanofi
Further product details are provided in the report……..
Interleukin-33 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin-33 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Interleukin-33 inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Interleukin-33 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin-33 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-33 inhibitors drugs.
Interleukin-33 inhibitors Report Insights
- Interleukin-33 inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Interleukin-33 inhibitors drugs?
- How many Interleukin-33 inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Interleukin-33 inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin-33 inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Interleukin-33 inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- AstraZeneca
- Regeneron Pharmaceuticals
- Sanofi
- Genentech
- Cantargia
- MEDI3506
- Itepekimab
- Astegolimab
- CAN-10
- Research program: IL1RAP-targeting antibody therapeutics
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Interleukin-33 inhibitors: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Interleukin-33 inhibitors – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Interleukin-33 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Interleukin-33 inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Itepekimab: Regeneron Pharmaceuticals/Sanofi
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MEDI3506: AstraZeneca
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- CAN-10: Cantargia
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Interleukin-33 inhibitors Key Companies
- Interleukin-33 inhibitors Key Products
- Interleukin-33 inhibitors- Unmet Needs
- Interleukin-33 inhibitors- Market Drivers and Barriers
- Interleukin-33 inhibitors- Future Perspectives and Conclusion
- Interleukin-33 inhibitors Analyst Views
- Interleukin-33 inhibitors Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
